Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback on this new experience.Tell us what you think(opens in new tab/window)

Elsevier
Publish with us
Shopping Cart
User account

Conference speaker

Anneliesa Anderson

AA

Anneliesa Anderson

Pfizer Inc, USA

Dr. Anderson is the Senior Vice President and Chief Scientific Officer for Vaccine Research & Development at Pfizer, and has over 30 years of pharmaceutical research experience.

She is responsible for the end-to-end research and development of all infectious disease vaccine programs in Pfizer’s portfolio, including those for Streptococcus pneumoniae, Respiratory Syncytial Virus, Neisseria meningitidis, COVID‑19, Influenza, Clostridioides difficile, and many others. Dr. Anderson earned her doctorate in biological sciences at the University of Warwick, has an extensive publication and patent portfolio, and has contributed to the licensure of numerous products, including the first US-licensed vaccine against invasive meningococcal disease, the first licensed mRNA-based vaccine, and a first-in-class antiviral against SARS-CoV-2.